INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
Corporate insider
LL

Lamattina John L

DirectorCIK 0001216074

EDGAR filingsOpen in network
Disclosed transactions15
Buys / sells0 / 7
Max Insider Score47
Connections1with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
42
LL
Lamattina John LDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale
SELL$857K
3,405 sh
Jun 10, 2026Jun 12, 2026
traded Jun 10, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    LIGAND PHARMACEUTICALS INCDirector · Nov 12, 2025
35
LL
Lamattina John LDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale
SELL
$64K
257 sh
Jun 10, 2026
Jun 12, 2026
traded Jun 10, 2026
+2d
SEC FORM 4

Evidence

35
LL
Lamattina John LDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale
SELL$174K
697 sh
Jun 10, 2026Jun 12, 2026
traded Jun 10, 2026
+2dSEC FORM 4

Evidence

35
LL
Lamattina John LDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale
SELL$58K
232 sh
Jun 10, 2026Jun 12, 2026
traded Jun 10, 2026
+2dSEC FORM 4

Evidence

5
LL
Lamattina John LDirector
LGNDLIGAND PHARMACEUTICALS INC
Grant or award
A—
836 sh
Jun 5, 2026Jun 9, 2026
traded Jun 5, 2026
+4dSEC FORM 4

Evidence

5
LL
Lamattina John LDirector
LGNDLIGAND PHARMACEUTICALS INC
Grant or award
A—
2,938 sh
Jun 5, 2026Jun 9, 2026
traded Jun 5, 2026
+4dSEC FORM 4

Evidence

22
LL
Lamattina John LDirector
LGNDLIGAND PHARMACEUTICALS INC
Option exercise
M$247K
2,161 sh
Mar 6, 2026Mar 31, 2026
traded Mar 6, 2026
+25dSEC FORM 4

Evidence

47
LL
Lamattina John LDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale
SELL$434K
2,161 sh
Mar 6, 2026Mar 31, 2026
traded Mar 6, 2026
+25dSEC FORM 4

Evidence

15
LL
Lamattina John LDirector
LGNDLIGAND PHARMACEUTICALS INC
Option exercise
M—
2,161 sh
Mar 6, 2026Mar 31, 2026
traded Mar 6, 2026
+25dSEC FORM 4

Evidence

15
LL
Lamattina John LDirector
LGNDLIGAND PHARMACEUTICALS INC
Option exercise
M—
2,034 sh
Nov 7, 2025Nov 12, 2025
traded Nov 7, 2025
+5dSEC FORM 4

Evidence

15
LL
Lamattina John LDirector
LGNDLIGAND PHARMACEUTICALS INC
Option exercise
M—
2,145 sh
Nov 7, 2025Nov 12, 2025
traded Nov 7, 2025
+5dSEC FORM 4

Evidence

22
LL
Lamattina John LDirector
LGNDLIGAND PHARMACEUTICALS INC
Option exercise
M$142K
2,145 sh
Nov 7, 2025Nov 12, 2025
traded Nov 7, 2025
+5dSEC FORM 4

Evidence

47
LL
Lamattina John LDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale
SELL$418K
2,034 sh
Nov 7, 2025Nov 12, 2025
traded Nov 7, 2025
+5dSEC FORM 4

Evidence

47
LL
Lamattina John LDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale
SELL$441K
2,145 sh
Nov 7, 2025Nov 12, 2025
traded Nov 7, 2025
+5dSEC FORM 4

Evidence

22
LL
Lamattina John LDirector
LGNDLIGAND PHARMACEUTICALS INC
Option exercise
M$141K
2,034 sh
Nov 7, 2025Nov 12, 2025
traded Nov 7, 2025
+5dSEC FORM 4

Evidence